# Phospholipase $C\zeta$ rescues failed oocyte activation in a prototype of male factor infertility

Michail Nomikos, Ph.D.,<sup>a,b</sup> Yuansong Yu, Ph.D.,<sup>a</sup> Khalil Elgmati, M.Sc.,<sup>a</sup> Maria Theodoridou, M.Sc.,<sup>a,b</sup> Karen Campbell, Ph.D.,<sup>c</sup> Vyronia Vassilakopoulou, M.Sc.,<sup>b</sup> Christos Zikos, Ph.D.,<sup>b</sup> Evangelia Livaniou, Ph.D.,<sup>b</sup> Nazar Amso, Ph.D.,<sup>a</sup> George Nounesis, Ph.D.,<sup>b</sup> Karl Swann, Ph.D.,<sup>a</sup> and F. Anthony Lai, Ph.D.<sup>a</sup>

<sup>a</sup> Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom; <sup>b</sup> National Center for Scientific Research "Demokritos," Aghia Paraskevi, Greece; and <sup>c</sup> IVF Wales, University Hospital of Wales, Heath Park, Cardiff, United Kingdom

**Objective:** To determine the effect of infertility-linked sperm phospholipase C $\zeta$  (PLC $\zeta$ ) mutations on their ability to trigger oocyte Ca<sup>2+</sup> oscillations and development, and also to evaluate the potential therapeutic utility of wild-type, recombinant PLC $\zeta$  protein for rescuing failed oocyte activation and embryo development.

Design: Test of a novel therapeutic approach to male factor infertility.

Setting: University medical school research laboratory.

Patient(s): Donated unfertilized human oocytes from follicle reduction.

**Intervention(s):** Microinjection of oocytes with recombinant human PLC $\zeta$  protein or PLC $\zeta$  cRNA and a Ca<sup>2+</sup>-sensitive fluorescent dye. **Main Outcome Measure(s):** Measurement of the efficacy of mutant and wild-type PLC $\zeta$ -mediated enzyme activity, oocyte Ca<sup>2+</sup> oscillations, activation, and early embryo development.

**Result(s):** In contrast to the wild-type protein, mutant forms of human sperm PLC $\zeta$  display aberrant enzyme activity and a total failure to activate unfertilized oocytes. Subsequent microinjection of recombinant human PLC $\zeta$  protein reliably triggers the characteristic pattern of cytoplasmic Ca<sup>2+</sup> oscillations at fertilization, which are required for normal oocyte activation and successful embryo development to the blastocyst stage.

**Conclusion(s):** Dysfunctional sperm PLC $\zeta$  cannot trigger oocyte activation and results in male factor infertility, so a potential therapeutic approach is oocyte microinjection of active, wild-type PLC $\zeta$  protein. We have demonstrated that recombinant human PLC $\zeta$  can

phenotypically rescue failed activation in oocytes that express dysfunctional PLCζ, and that this intervention culminates in efficient blastocyst formation. (Fertil Steril® 2013;99:76–85. ©2013 by American Society for Reproductive Medicine.)

Key Words: Fertilization, male infertility, oocyte activation, phospholipase C, PLC-zeta

**Discuss:** You can discuss this article with its authors and with other ASRM members at http://fertstertforum.com/nomikosm-plc-zeta-oocyte-activation-male-infertility/



Use your smartphone to scan this QR code and connect to the discussion forum for this article now.\*

\* Download a free QR code scanner by searching for "QR scanner" in your smartphone's app store or app marketplace.

ocyte (or egg) activation, the earliest step of mammalian embryonic development after fertilization, is triggered by a characteristic series of large cytoplasmic Ca<sup>2+</sup> transients known as Ca<sup>2+</sup> oscillations (1, 2). This striking  $Ca^{2+}$  signaling phenomenon is both necessary and sufficient for the completion of all the events of egg activation such as cortical granule exocytosis, which acts to prevent polyspermy, the resumption

Received June 23, 2012; revised August 15, 2012; accepted August 20, 2012; published online September 21, 2012.

M.N. has nothing to disclose. Y.Y. has nothing to disclose. K.E. is a research scholar of the Libyan government. M.T. is a research scholar of NCSR Demokritos. K.C. has nothing to disclose. V.V. is a research scholar of NCSR Demokritos. C.Z. has nothing to disclose. E.L. has nothing to disclose. N.A. has nothing to disclose. G.N. has nothing to disclose. K.S. holds a patent for PLCζ. F.A.L. holds a patent for PLCζ.

Supported by a Wellcome Trust grant 080701/Z/06/Z (to F.A.L. and K.S., Cardiff University, UK).

Reprint requests: F. Anthony Lai, Ph.D., WHRI Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom (E-mail: lait@cf.ac.uk); and Michail Nomikos, Ph.D. (E-mail: mixosn@yahoo.com).

Fertility and Sterility® Vol. 99, No. 1, January 2013 0015-0282/\$36.00 Copyright ©2013 American Society for Reproductive Medicine, Published by Elsevier Inc. Open access under CC BY license. http://dx.doi.org/10.1016/j.fertnstert.2012.08.035

and completion of meiosis, and pronuclei formation (3). Over the last decade, there has been growing evidence that indicating the physiologic agent responsible for generating Ca<sup>2+</sup> oscillations and the subsequent egg activation is a testisspecific isoform of phospholipase C, PLC $\zeta$  (4–7). These studies culminate in the proposal that PLC $\zeta$  is delivered by the fertilizing sperm into the ooplasm, whereupon it hydrolyzes the membrane phospholipid substrate, phosphatidylinositol 4,5 bisphosphate (PIP<sub>2</sub>), to trigger cytoplasmic  $Ca^{2+}$ oscillations via the inositol 1,4,5trisphosphate (InsP<sub>3</sub>) intracellular  $Ca^{2+}$  signaling pathway (3–5). The smallest known mammalian PLC isozyme of  $\sim$ 70 kd, PLC $\zeta$  consists of four EF hands, the catalytic X and Y domains, and a C2 domain (4, 5). Each of the individual PLC $\zeta$  domains appears to have an essential role in conferring the distinct biochemical characteristics and the unique mode of regulation of this gamete-specific PLC isozyme (8–14).

The fundamental role of PLCζ in mammalian fertilization has been further highlighted by recent clinical studies that have directly linked abnormal PLCZ protein expression profiles with documented cases of male infertility (15-18). Sperm from patients that displayed either reduced PLC protein abundance or that expressed mutated forms of PLC $\zeta$ were correlated specifically with failed fertilization after intracytoplasmic sperm injection (ICSI) treatment, which was due empirically to the inability of such sperm to initiate the vital Ca<sup>2+</sup> oscillations required for egg activation (15-18). The observation of aberrant sperm PLC $\zeta$  protein expression in infertile males suggests that the wild-type PLC $\zeta$  protein could be used as a potential therapy to overcome such cases of infertility. However, it is not known whether the wild-type human PLCζ protein is able to physiologically activate eggs in the presence of mutant PLC<sup>2</sup> and if this would successfully lead to normal embryo development.

We now show that purified recombinant human PLC $\zeta$ protein is capable of hydrolyzing PIP<sub>2</sub> with a similar  $Ca^{2+}$  dependence to mouse PLCZ, and that it can also induce cytoplasmic Ca<sup>2+</sup> oscillations after microinjection into both mouse and human eggs, leading to successful egg activation and early embryo development. We also demonstrate the deleterious effect of male-infertility-linked PLCζ mutations on both Ca<sup>2+</sup> oscillations and PIP<sub>2</sub> hydrolysis activity. Notably, mouse eggs expressing the mutant human PLC $\zeta$  were unable to activate normally and failed to commence embryo development. However, this infertile phenotype could be effectively rescued by microinjection of the wild-type human PLCζ protein, leading to Ca<sup>2+</sup> oscillations and successful early embryogenesis up to the blastocyst stage. Our findings demonstrate the potential utility of PLC<sup>2</sup> protein in in vitro fertilization (IVF) treatment, thus providing a novel therapeutic agent that may help to overcome those cases of egg activation failure caused by deficient or defective forms of PLCζ in human sperm.

#### MATERIALS AND METHODS Expression Plasmid Construction and cRNA Synthesis

A pCR3 plasmid construct encoding human PLC $\zeta$ -luciferase (19) was subjected to site-directed mutagenesis (QuikChange II; Stratagene) to generate the PLC $\zeta^{H233L}$  and PLC $\zeta^{H398P}$  mutants. Wild-type human PLC $\zeta$  (GenBank #AF532185) and the H233L and H398P mutants were amplified by polymerase chain reaction (PCR) from the corresponding pCR3 plasmid by use of Phusion polymerase (Finnzymes) to incorporate a 5' Sall site and a 3' NotI site and were cloned into a modified pET expression vector (pETMM60). The primers used for amplification of wild-type and mutant PLC $\zeta$  were: 5'-CCTAGTCGACA TGGAAATGAGATGGTTTTTGTC-3' (forward) and 5'-CTAA GCGGCCGCTCATCTGACGTACCAAACATAAAC-3' (reverse).

Similarly, mouse PLCζ (GenBank #AF435950) was amplified by PCR from a pCR3-mouse PLCζ-luciferase construct (8) in the same manner and cloned into pETMM60. The mouse PLCζ primers used were: 5'-CTCAGTCGACATGGAAAGCCAA CTTCATGA-3' (forward) and 5'-ATCAGCGGCCGCTCACTCTCT GAAGTACCAAAC-3' (reverse). Rat PLC $\delta$ 1 (GenBank #M20637) was amplified by PCR from a pGEX-5X2-PLC $\delta$ 1 construct (8) in the same manner and cloned into pETMM60. The rat PLC $\delta$ 1 primers used were: 5'-CTCAGTCGACATGGACTCGGGTAGG GACTTCC-3' (forward) and 5'-ATCAGCGGCCGCTCAGTCCTG GATGGAGATCTT-3' (reverse). After linearization of the various luciferase-tagged PLC plasmid constructs, complementary RNA (cRNA) encoding the respective PLC was synthesized (13, 14) by use of the mMessage Machine T7 kit (Ambion) and a poly(A) tailing kit (Ambion), as per the manufacturer's instructions.

#### **Protein Expression and Purification**

For the NusA-PLC fusion protein expression studies, *Escherichia coli* (Rosetta [DE3]; Novagen) transformed with the appropriate pETMM60 plasmid was cultured at 37°C until  $A_{600}$  reached 0.6, and NusA-fusion protein expression was induced for 18 hours at 16°C with 0.1 mM isopropyl- $\beta$ -D-thiogalacto-pyranoside (IPTG; Promega). Cells were harvested (6,000 × *g* for 10 minutes), resuspended in phosphate-buffered saline (PBS) containing a protease inhibitor mixture (EDTA-free; Roche), and sonicated 4 × 15 seconds on ice. Soluble NusA-fusion proteins were then purified by affinity chromatography on Ni-NTA resin after standard procedures (Qiagen) and elution with 275 mM imidazole. Eluted proteins were dialyzed overnight (10,000 MWCO; Pierce) at 4°C against 4 L of PBS, and concentrated with centrifugal concentrators (Sartorius; 10,000 MWCO).

#### Assay of PLC Activity

The PIP<sub>2</sub> hydrolytic enzyme activity of recombinant PLC proteins was assayed as previously described elsewhere (8, 11, 13). The final concentration of PIP<sub>2</sub> in the reaction mixture was 220  $\mu$ M, containing 0.05  $\mu$ Ci of [<sup>3</sup>H]PIP<sub>2</sub>. The hydrolysis assay conditions were optimized for linearity of enzyme kinetic activity, requiring a 10-minute incubation of 20 pmol of PLC $\zeta$  protein sample at 25°C. In assays to determine dependence on PIP<sub>2</sub> concentration, 0.05  $\mu$ Ci of [<sup>3</sup>H]PIP<sub>2</sub> was mixed with cold PIP<sub>2</sub> to give an admixture of the appropriate final PIP<sub>2</sub> concentration. In assays examining PLC Ca<sup>2+</sup> sensitivity, Ca<sup>2+</sup> buffers were prepared by EGTA/CaCl<sub>2</sub> admixture, as previously described elsewhere (8, 13).

#### Preparation of Gametes and Analysis of Embryos

Experiments were carried out with mouse eggs in HEPESbuffered potassium simplex optimized medium (H-KSOM) as previously described elsewhere (8, 12, 14). Eggs obtained from superovulated mice were microinjected 14.5 to 15.5 hours after human chorionic gonadotropin (hCG) administration (14, 19). All procedures were in accordance with the UK Home Office Animals Procedures Act and were approved by the Cardiff University Animals Ethics Committee. For the egg activation and embryo development studies, recombinant human PLC $\zeta$  protein-injected mouse eggs were kept in KSOM containing 5  $\mu$ g/mL cytochalasin B for 6 hours. After pronuclei formation was observed, the activated eggs were cultured in KSOM at 37°C in 5% CO<sub>2</sub>, and the different stages of the early embryo development process were observed and counted at 6, 24, 48, 72, and 96 hours.

# Microinjection and Measurement of Intracellular Ca<sup>2+</sup> and Luciferase Expression

Mouse eggs were washed in M2 and microinjected either with complementary RNA (cRNA) or recombinant protein diluted in injection buffer (120 mM KCl, 20 mM HEPES, pH 7.4). All injections were 3% to 5% of the egg volume (10, 12). The cRNA or recombinant protein was mixed with an equal volume of 1 mM Oregon Green BAPTA dextran (Molecular Probes). Eggs were maintained in H-KSOM containing 100  $\mu$ M luciferin and were imaged on a Nikon TE2000 or Zeiss Axiovert 100 microscope equipped with a cooled intensified CCD camera (Photek Ltd.). Cytoplasmic Ca<sup>2+</sup> changes were monitored in these eggs for 4 hours after injection by measuring the Oregon Green BAPTA-dextran fluorescence with low-level excitation light from a halogen lamp (11, 14).

At the end of  $Ca^{2+}$  measurements, the same set of eggs was then monitored for luminescence (i.e., indicating recombinant protein concentration) by integrating light emission (in the absence of fluorescence excitation) for 20 minutes using the same intensified CCD camera (18, 19). Notably, the fluorescence signals were typically 10 to 100 times greater than the luminescence signals. The  $Ca^{2+}$ measurements for an egg were further analyzed only if the same egg was also luminescent. The luminescence reading from eggs was converted into an amount of luciferase by use of a standard curve that was generated by placing eggs in a luminometer that had been previously calibrated by microinjection with known amounts of luciferase protein (Sigma) (8, 21).

### Immunofluorescence of Sperm PLCζ

The anti-PLC $\zeta$ , V-37, polyclonal antibody was raised in rabbits against a 16-mer-peptide sequence (<sup>8</sup>SKIQDDFRGGKIN-LEK<sup>23</sup>) of human PLC $\zeta$  protein and was affinity-purified as per the manufacturer's instructions (Invitrogen). Anti-NusA and anti- $\beta$ -actin mouse monoclonal antibodies were purchased from Santa Cruz Biotechnology.

Human sperm samples washed with PBS (pH 7.4) were fixed with 4% ethanol-free formaldehyde (Polysciences Inc.) for 30 minutes at 4°C. Fixed samples were resuspended in PBS and spotted onto 0.1% poly L-lysine-coated (Sigma-Aldrich) coverslips and dried for 2 hours at 37°C before permeabilization with 1% Triton X-100 for 1 hour at 23°C. After blocking with 5% normal goat serum (Invitrogen) for 30 minutes, the samples were incubated with V-37 antibody (rabbit IgG in PBS containing 5% normal goat serum) overnight at 4°C, washed with PBS, then incubated with Alexa-488conjugated goat anti-rabbit antibody (Invitrogen) for 45 minutes. The samples were mounted on slides with antifading reagent (Invitrogen) and observed using a SP5 confocal microscope (Leica) under  $\times 100$  oil immersion objective; the collected images were edited with ImageJ (http://rsbweb.nih. gov/ij).

### **SDS-PAGE and Immunoblot Analysis**

Fresh human sperm samples washed with PBS (pH 7.4) were mixed with  $5 \times$  SDS sample buffer, vortexed briefly, and sonicated for 5 seconds on ice. Sperm samples and recombinant proteins were separated by SDS-PAGE, as previously described elsewhere (8, 18). Separated proteins were transferred onto polyvinylidene difluoride membrane and incubated overnight at 4°C with the appropriate primary antibody. Detection of horseradish peroxidase-coupled secondary antibody was achieved by use of Super Signal West Dura (Pierce) and a Bio-Rad ChemiDoc gel documentation system for image capture (11, 20).

The human sperm and oocytes used in this study were donated by patients attending the IVF Wales clinic at the University Hospital of Wales, Cardiff, UK. The current project and all associated procedures were approved by the local South East Wales Research Ethics Committee and also by the UK Human Fertilisation and Embryology Authority (R0161).

### RESULTS

#### Native and Recombinant Human PLCζ Analysis

The expression and distribution of native PLCZ in fertile human sperm was examined by immunoblot and immunofluorescence analysis on ejaculated sperm from a man whose partner had achieved successful pregnancy via ICSI. An affinity-purified, anti-PLC polyclonal antibody positively detected a single, immunoreactive 70 kd protein corresponding to human PLC $\zeta$  (5), with the control anti- $\beta$ -actin antibody identifying a 42 kd human  $\beta$ -actin band (Fig. 1A). Immunofluorescence analysis revealed native PLCZ localization primarily in the equatorial region of the sperm head with some additional acrosomal staining (see Fig. 1B). Equatorial localization of PLC $\zeta$  is congruent with fusion of this sperm region with the oocyte plasma membrane at fertilization, thus facilitating early entry of PLC $\zeta$  into the ooplasm (1-3). The acrosomal staining suggests either an additional role of PLC $\zeta$  in earlier steps of fertilization that remains undefined, or is due to nonspecific immunoreactivity, although the immunoblot detection of only a single 70 kd protein (see Fig. 1A) would be consistent with the former suggestion.

Recombinant human PLC $\zeta$  was expressed as a NusAhexahistidine fusion protein in *E. coli* and purified by Ni-NTA affinity chromatography. Our earlier use of plasmid vectors comprising only the hexahistidine tag (i.e., without a fusion protein, such as NusA) provided reliable recombinant PLC $\zeta$  protein expression, but it did not effectively yield soluble, functional PLC $\zeta$  (unpublished data). In contrast, significant expression of soluble NusA-PLC $\zeta$  was observed, and the affinity-purified human PLC $\zeta$  fusion protein, after SDS-PAGE and immunoblot analysis, displayed the predicted ~130 kd molecular mass (NusA ~60 kd + 70 kd *hPLC\zeta*)



human sperm. (A) Immunoblot analysis of PLC<sup>r</sup> protein in human sperm. Sperm cells (25,000 per lane) were analyzed by 9% SDS-PAGE, proteins were electrophoretically transferred, and the blot membrane was incubated either with affinity-purified, anti-PLCC polyclonal antibody (V-37; 1:7,500 dilution; left panel) or with anti- $\beta$ -actin monoclonal antibody (1:2,500 dilution; *right panel*). (B) images Representative confocal microscope of PLCζ immunofluorescence in human sperm after fixing and immunostaining with anti-PLCζ polyclonal antibody (V-37; 1:1,000 dilution) showing that the native PLC $\zeta$  in this IVF patient localizes to the equatorial and acrosomal region of the sperm head.

Nomikos. PLCÇ rescue of failed egg activation. Fertil Steril 2013.

(Fig. 2A). Enzymatic determination of [<sup>3</sup>H]PIP<sub>2</sub> hydrolysis activity for the purified human PLCZ, mouse PLCZ, and rat PLC $\delta$ 1 fusion proteins (8, 11, 13, 18) (see Fig. 2B) reveals the human PLCζ to have 42% higher specific activity than mouse PLC $\zeta$  (655  $\pm$  36 vs. 460  $\pm$  24 nmol/min/mg), but both of these PLCs had much lower specific activity (27% to 38%) relative to *PLC* $\delta$ 1 (1,703  $\pm$  52 nmol/min/mg) (Table 1). The relative  $Ca^{2+}$  sensitivity of  $[^{3}H]PIP_{2}$ hydrolysis was determined between 0.1 nM to 0.1 mM Ca<sup>2+</sup> (see Fig. 2C), yielding an  $EC_{50}$  value for human PLC $\zeta$  that was near identical with mouse PLC $\zeta$  (70 vs. 64 nM Ca<sup>2+</sup>), but this was in sharp contrast with the  $\sim$ 80-fold higher PLC $\delta$ 1 EC<sub>50</sub> value of 5,327 nM (see Table 1). The marked EC<sub>50</sub> disparity is consistent with previous studies of PLC isoform  $Ca^{2+}$  sensitivity that indicated that only PLC $\zeta$  would be near-optimally activated to hydrolyze its PIP<sub>2</sub> substrate at the  $\sim 100$  nM resting Ca<sup>2+</sup> levels in mammalian eggs (6, 8).



Expression and enzymatic characterization of recombinant wild-type human phospholipase C $\zeta$  (PLC $\zeta$ ) protein. (A) One  $\mu$ g of bacteriallyexpressed, affinity-purified NusA-hPLC fusion protein analyzed by 7% SDS-PAGE (left panel) or by immunoblot analysis with either anti-PLC c polyclonal (V-37; 1:10,000 dilution; middle panel) or anti-NusA monoclonal antibody (1:20,000 dilution; right panel). (B) The PIP<sub>2</sub> hydrolysis enzyme activities of recombinant hPLC<sub>2</sub>, mPLC<sub>2</sub>, and rPLC $\delta$ 1 purified by nickel affinity chromatography as NusA-fusion proteins (20 pmol) determined with the [<sup>3</sup>H]PIP<sub>2</sub> cleavage assay, n 3  $\pm$  standard error of the mean (SEM), using two different preparations of recombinant protein and with each experiment performed in duplicate. In control experiments with NusA alone, no specific PIP<sub>2</sub> hydrolysis activity was observed (data not shown). (C) Effect of varying [Ca<sup>2+</sup>] on the normalized PIP<sub>2</sub> hydrolysis enzyme activity of purified, recombinant hPLCζ, mPLCζ, and rPLCδ1 NusAfusion proteins. For these assays,  $n = 2 \pm SEM$  using two different batches of recombinant proteins and with each experiment performed in duplicate.

Nomikos. PLCÇ rescue of failed egg activation. Fertil Steril 2013.

Microinjection of recombinant wild-type human PLC $\zeta$ into mouse and human eggs revealed that it possesses a potent ability to induce cytoplasmic Ca<sup>2+</sup> oscillations (Fig. 3A, top and bottom traces, respectively), matching that observed after microinjection of native sperm extracts (2, 3). The NusA protein microinjection alone did not cause any Ca<sup>2+</sup>

### TABLE 1

Specific enzyme activity and  $Ca^{2+}$ -dependent [<sup>3</sup>H]PIP<sub>2</sub> hydrolysis activity of purified NusA-PLC proteins.

NusA-PLC fusion protein	PIP <sub>2</sub> hydrolytic enzyme activity (nmol/min/mg)	Ca <sup>2+</sup> -dependence of enzyme activity EC <sub>50</sub> (nM)			
Human PLCζ	$655\pm36$	70			
Mouse PLCζ	$460 \pm 24$	64			
Rat PLC $\delta$ 1	$1,703\pm52$	5,327			
Note: Summary of the specific hydrolytic enzyme activity and the EC <sub>1</sub> , values of $C_2^{2+}$ dependence					

Note: Summary of the specific hydrolytic enzyme activity and the EC<sub>50</sub> values of Ca<sup>+-</sup> dependent enzyme activity for [<sup>3</sup>H]PIP<sub>2</sub> hydrolysis that was determined as described in Materials and Methods; the data were analyzed by nonlinear regression analysis (GraphPad Prism 5) for the affinity-purified NusA-hexahistidine fusion proteins for hPLC $\zeta$ , mPLC $\zeta$ , and rPLC $\delta$ 1 (see Fig. 2B and C).

Nomikos. PLCÇ rescue of failed egg activation. Fertil Steril 2013.

changes (see Fig. 3A, middle trace). The minimal PLC $\zeta$  concentration required for a physiologic pattern of Ca<sup>2+</sup> oscillations was 0.0167 mg/mL, indicating that the amount of human PLC $\zeta$  in mouse eggs able to induce Ca<sup>2+</sup> oscillations and early embryogenesis was ~80 fg/egg. This

**FIGURE 3** 

is in the same range as the estimated PLC $\zeta$  content within a single sperm (4). Moreover, we observed that highly efficient early embryo development, from pronuclei formation up to the multicellular blastocyst stage, was also specifically initiated by the human PLC $\zeta$  protein microinjection (see Fig. 3B). The successful early development to the blastocyst embryo stage observed with wild-type PLC $\zeta$ -injected eggs was >50% (see Fig. 3B), a value that is very similar to that previously obtained after microinjection of cRNA encoding luciferasetagged human PLC $\zeta$  (19).

# In Vivo and In Vitro Analysis of Infertility-Linked PLC $\zeta$ Mutations

The first direct link between male infertility and a defective PLC $\zeta$  gene was made after identification of a PLC $\zeta$  point mutation in an infertile man with failed fertilization after ICSI treatment (16). This PLC $\zeta$  catalytic domain mutation of a conserved histidine residue to a proline (H398P) (Fig. 4A) disrupts both enzymatic PIP<sub>2</sub> hydrolysis and Ca<sup>2+</sup> release activity in mouse eggs (18). A second PLC $\zeta$  mutation, also in the



Recombinant human phospholipase C $\zeta$  (PLC $\zeta$ ) protein induces Ca<sup>2+</sup> oscillations in mouse and human eggs and initiates early embryo development. (A) Representative fluorescence (au: arbitrary units) recordings reporting the Ca<sup>2+</sup> concentration changes in a mouse and human egg after microinjection of human PLC $\zeta$  recombinant protein (*top and bottom trace*, respectively). Microinjection of NusA alone does not induce Ca<sup>2+</sup> release in mouse eggs (*middle trace*). (B) Micrographs illustrating mouse embryos at the various early developmental stages (pronuclear formation [PN], two-cell and eight-cell stages, and blastocyst stage) achieved after egg microinjection with ~80 fg of purified, wild-type human PLC $\zeta$  recombinant protein (0.0167 mg/mL). The optimal efficiency of blastocyst formation achieved by microinjection of hPLC $\zeta$  into mouse eggs was 50% to 60%.

Nomikos. PLCÇ rescue of failed egg activation. Fertil Steril 2013.

#### **FIGURE 4**



Effect of H233L and H398P mutations on  $Ca^{2+}$  oscillation-inducing activity of human phospholipase C $\zeta$  (PLC $\zeta$ ) in mouse eggs. (A) Schematic representation of human PLC $\zeta$  domain structure identifying the location of H233L and H398P mutations within the X and Y catalytic domains, respectively. (B) Fluorescence and luminescence recordings reporting the cytosolic  $Ca^{2+}$  changes (*black traces;*  $Ca^{2+}$ ) and luciferase-PLC $\zeta$  expression level (in counts per second, cps), respectively, in unfertilized mouse eggs after the microinjection of cRNA encoding luciferase-tagged, wild-type human PLC $\zeta$ , and the PLC $\zeta^{H233L}$  and PLC $\zeta^{H398P}$  mutants. Panels on the right display the integrated luminescence image of individual mouse eggs after cRNA microinjection of either wild-type or mutant PLC $\zeta$ . The relatively low luminescence values achieved, corresponding to femtogram levels of PLC $\zeta$  protein expressed in each cRNA-microinjected egg, are intended to mimic the approximate amount of PLC $\zeta$  that is delivered by entry of a single sperm.

Nomikos. PLCÇ rescue of failed egg activation. Fertil Steril 2013.

catalytic domain (H233L) (see Fig. 4A), has recently been identified (17), although this particular histidine residue is not conserved.

To enable the comparison of relative recombinant protein expression by luminescence measurement (8, 21), we prepared luciferase-fusion constructs of each of these human PLC $\zeta$  mutants as well as wild-type PLC $\zeta$  for microinjection into mouse eggs. Prominent Ca<sup>2+</sup> oscillations (~9 spikes/2 hours) were observed in wild-type PLC $\zeta$  cRNA-injected mouse eggs, with the first Ca<sup>2+</sup> spike occurring after ~25 minutes at a luminescence reading of 0.07 counts per second (Table 2),

corresponding to expression of ~29 fg PLC $\zeta$ /egg (see Fig. 4B, top trace; see Table 2). Microinjection of mutant PLC $\zeta^{H398P}$  cRNA totally failed to cause any Ca<sup>2+</sup> oscillations in mouse eggs (see Fig. 4B, middle trace) (16), consistent with our recent findings for the equivalent mouse mutant (PLC $\zeta^{H435P}$ ) (18). It is interesting that, with the other catalytic domain mutation, the PLC $\zeta^{H233L}$  cRNA produced a dramatic reduction in Ca<sup>2+</sup> oscillation frequency compared with that of wild type (see Fig. 4B, bottom trace), with only ~2.8 spikes/2 hours observed (see Table 2). Moreover, there was also a significant delay in initiation of cytoplasmic Ca<sup>2+</sup>

### TABLE 2

Expression of microinjected cRNA encoding luciferase-tagged wild-type phospholipase C $\zeta$  (PLC $\zeta$ ) mutants PLC $\zeta^{H233L}$  and PLC $\zeta^{H398P}$  in unfertilized mouse eggs.

PLCζ-luciferase injected	Ca <sup>2+</sup> oscillations (spikes/2 h)	Peak luminescence (cps)	Time to 1st spike (min)	Luminescence at 1st spike (cps)	
ΡLCζ <sup>WT</sup> ΡLCζ <sup>H233L</sup> ΡLCζ <sup>H398P</sup>	$\begin{array}{c} 9.02 \pm 0.037 \\ 2.84 \pm 0.076 \\ \end{array}$	$\begin{array}{c} 0.42  \pm  0.020 \\ 0.40  \pm  0.050 \\ 0.39  \pm  0.020 \end{array}$	~25 ~190 —	$\begin{array}{c} 0.07 \pm 0.005 \\ 0.34 \pm 0.040 \\ \end{array}$	
Note: Values are mean $\pm$ standard error of the mean. The Ca <sup>2+</sup> oscillation-inducing activity (Ca <sup>2+</sup> spike number in 2 hours; time to first spike) and the simultaneously-measured PLCC-luciferase					

Note: Values are mean ± standard error of the mean. The Ca<sup>++</sup> oscillation-inducing activity (Ca<sup>++</sup> spike number in 2 hours; time to first spike) and the simultaneously-measured PLC2-luciferase fusion protein luminescence levels (peak luminescence; luminescence at first spike) are summarized for mouse eggs that had been microinjected, as described in Materials and Methods, with cRNA encoding one of the following human PLC2-luciferase constructs: wild-type PLC2; the PLC2<sup>H233L</sup> or PLC2<sup>H233L</sup> or PLC2<sup>H398P</sup> mutant (see Fig. 4B). cps = counts per second.

Nomikos. PLCC rescue of failed egg activation. Fertil Steril 2013.

oscillations in the egg, with the first Ca<sup>2+</sup> spike appearing after ~190 minutes at a luminescence value of 0.34 counts per second. Hence, whereas PLC $\zeta^{H398P}$  completely abrogates, the PLC $\zeta^{H233L}$  mutation substantially reduces the frequency of Ca<sup>2+</sup> oscillations in mouse eggs, with both resulting in a failure to activate embryo development.

The in vitro PIP<sub>2</sub> hydrolysis activity of the wild-type human PLC $\zeta$ , and the PLC $\zeta^{H233L}$  and PLC $\zeta^{H398P}$  mutant proteins was compared after their expression in *E. coli*, purification by Ni-NTA affinity chromatography, and gel/immunoblot analysis (Fig. 5A). Enzyme specific activity values obtained for each protein reveal that the PLC $\zeta^{H233L}$  mutant retains only 24% of the activity of wild-type PLC $\zeta$  (157 ± 48 vs. 655 ± 36 nmol/min/mg), and the PLC $\zeta^{H398P}$  mutant almost completely fails to hydrolyze [<sup>3</sup>H]PIP<sub>2</sub>. These enzymatic data indicate that both of these histidine mutations when introduced into human PLC $\zeta$  dramatically diminish their PIP<sub>2</sub> hydrolytic activity, thus directly explaining why the cRNA microinjection of these PLC $\zeta$  mutants into unfertilized mouse eggs fails to induce normal egg activation.

## Rescue of Egg Activation Failure by Microinjection of Human PLC<sup>C</sup> Protein

We further investigated whether the purified, recombinant wild-type human PLC $\zeta$  protein would be able to rescue the egg activation failure observed after expression of the infertility-linked human  $PLC\zeta^{H398P}$  and  $PLC\zeta^{H233L}$  mutants in mouse eggs (see Fig. 4B, middle and bottom traces, respectively). For this experiment, two different sets of mouse eggs were microinjected with cRNA encoding either the human  $PLC\zeta^{H398P}$  or  $PLC\zeta^{H233L}$  mutant. During the 3-hour time period after the injection of the mutant cRNAs, which enabled both of the mutant PLC<sub>2</sub> proteins to be expressed (>0.30 counts per second) at the physiologic level required for fertilization (i.e., the amount of PLCzeta normally present in a single sperm), there were no detectable  $Ca^{2+}$  changes observed in either set of mouse eggs (Fig. 6, short arrow-traces on left). At this 3-hour post-cRNA time point, the same eggs were again microinjected, but this time with  $\sim$ 80 fg of the purified recombinant, human wild-type PLC $\zeta$  protein.

This intervention with microinjected protein immediately resulted in the highly effective induction of a normal pattern of  $Ca^{2+}$  oscillations (see Fig. 6, long arrow-traces in middle), leading to efficient physiologic egg activation and successful

early embryo development up to the multicellular blastocyst stage (see Fig. 6, micrographs on right). The efficiency of development to the blastocyst stage for the wild-type PLC $\zeta$  protein-injected eggs was close to 60%. The observation of efficacious phenotypic rescue of mutant PLC $\zeta$ -mediated egg



Expression, purification, and enzyme activity of the PLC $\zeta^{H233L}$  and PLC $\zeta^{H398P}$  mutant proteins. (A) The affinity-purified NusA-fusion proteins for PLC $\zeta^{H233L}$  and PLC $\zeta^{H398P}$  (1  $\mu$ g) analyzed by 7% SDS-PAGE (*left panel*) or by immunoblot analysis using anti-PLC $\zeta$  polyclonal (V-37; 1:10,000 dilution; *middle panel*) or anti-NusA monoclonal antibody (1:20,000 dilution; *right panel*). (B) The [<sup>3</sup>H] PIP<sub>2</sub> hydrolysis activity of the purified PLC $\zeta^{H233L}$  and PLC $\zeta^{H398P}$  proteins, n = 3 ± standard error of the mean, determined using two different preparations of recombinant protein and with each experiment performed in duplicate.

Nomikos. PLCC rescue of failed egg activation. Fertil Steril 2013.

### **FIGURE 6**



Egg activation failure with mutant forms of human phospholipase C $\zeta$  (PLC $\zeta$ ) rescued by microinjection of recombinant, wild-type human PLC $\zeta$  protein. The traces on the left report the Ca<sup>2+</sup> concentration changes observed in unfertilized mouse eggs after microinjection with the cRNA for the mutants PLC $\zeta^{H398P}$  (*short arrow, upper panel*) and PLC $\zeta^{H233E}$  (*short arrow, lower panel*). After a period of 3 hours to enable femtogram expression of the mutant PLC $\zeta$  proteins, a second microinjection of ~80 fg of the affinity-purified, wild-type hPLC $\zeta$  recombinant protein was performed as described in **Figure 3** (*long arrows, upper and lower panels*), approximating the amount of native hPLC $\zeta$  in a single sperm. The two panels on the right display representative micrographs illustrating the mouse embryos at the blastocyst developmental stage that were observed 96 hours after microinjection of the human PLC $\zeta$  recombinant protein into each mouse egg. *Nomikos. PLC* rescue of failed egg activation. Fertil 2013.

activation failure suggests that the direct microinjection of active, wild-type human PLC $\zeta$  protein could potentially be used as a therapy in specific cases of failed ICSI due to defective PLC $\zeta$  in human sperm.

### DISCUSSION

Since the discovery of PLC $\zeta$  a decade ago (4), mounting evidence has strongly supported the notion that sperm-derived PLC $\zeta$  is the sole physiologic trigger of egg activation during mammalian fertilization (3, 22, 23). Upon sperm-egg fusion, it is believed that PLC $\zeta$  is introduced into the ooplasm and catalyses PIP<sub>2</sub> hydrolysis to generate InsP3. The intracellular Ca<sup>2+</sup> release triggered by InsP3 produces the characteristic cytoplasmic Ca<sup>2+</sup> oscillations that result in egg activation, and this initiates the embryo development process. Since then, PLC $\zeta$  has been identified in many different mammalian species, suggesting that it could play a pivotal role at fertilization in all mammals. Furthermore, recent clinical reports have linked reduced protein expression levels and abnormal forms of PLC $\zeta$  with human male infertility (15–18, 24).

Although ICSI is a powerful technique that is extensively used by IVF clinics to overcome many conditions of male infertility, clinical studies have identified men whose sperm repeatedly fail to fertilize after ICSI due to egg activation failure. The sperm that fail at ICSI cannot induce the Ca<sup>2+</sup> oscillations required for activation, and recent evidence indicates that this infertile phenotype is associated with defective sperm PLC $\zeta$ protein in these patients, caused either by a low level of sperm PLCζ protein expression or by genetic mutations resulting in a dysfunctional PLCζ in sperm (15–18, 24).

Despite the major role of PLC<sub>2</sub> in mammalian fertilization, thus far only purified recombinant mouse PLC<sup>2</sup> has been successfully used to study in vitro biochemical properties and the regulatory mechanisms underlying PLC<sup>2</sup> function (6, 8, 9, 11, 13). In this study, we prepared recombinant human PLCζ protein fused to NusA, a fusion protein known to greatly enhance the solubility and stability of recombinant proteins (25). Human PLC $\zeta$  is present as a 70 kd protein at the equatorial region in sperm (see Fig. 1). The purified human PLCζ protein exhibited higher in vitro PIP<sub>2</sub> hydrolysis activity than recombinant mouse PLC $\zeta$ , whereas the EC<sub>50</sub> for Ca<sup>2+</sup> sensitivity was very similar for both recombinant proteins (see Fig. 2; see Table 1). Microinjection of recombinant, wild-type human PLC $\zeta$  protein induced Ca<sup>2+</sup> oscillations in both mouse and human eggs (see Fig. 3) and successfully activated mouse early embryo development up to the blastocyst stage.

The estimated amount of human PLC $\zeta$  protein in mouse eggs that was required to efficiently induce Ca<sup>2+</sup> oscillations and embryogenesis was ~80 fg/egg (3–5 pL of 0.0167 mg/ mL), which is entirely consistent with the PLC $\zeta$  levels previously shown to be able to trigger egg activation and efficient development of mouse eggs (4, 19). Recombinant mouse PLC $\zeta$ synthesized by baculovirus expression was less efficient at inducing Ca<sup>2+</sup> oscillations in mouse eggs compared with recombinant human PLC $\zeta$ , requiring an estimated 300 fg/ egg (6). In our preliminary studies using recombinant human PLC<sup>2</sup> expressed alone, without the accompanying presence of a fusion protein to assist in stabilizing enzyme activity, we observed very poor ability to generate Ca<sup>2+</sup> oscillations. These observations are entirely consistent with the very recent report using human PLCζ expressed without a fusion protein partner that required injection of 5,000 to 10,000 fg/egg to cause Ca<sup>2+</sup> oscillations and did not result in embryo development to the blastocyst stage (29). Thus, our strategic use of NusA as an efficient fusion protein partner appears to be important for the recovery of significant levels of soluble human PLCZ. Importantly, this enzymatically active PLC $\zeta$  is capable of effecting successful embryo development when injected into mammalian eggs (see Fig. 3B), via generation of the characteristic  $Ca^{2+}$ oscillations that mimic the physiologic egg activation phenomenon observed at fertilization (see Fig. 3A).

To investigate whether injection of recombinant human PLCζ protein would be able to rescue the failed egg activation caused by infertility-linked PLCζ mutants, we assessed the effect of two novel point mutations identified in the PLCZ gene that have previously been specifically linked to male infertility (16, 17, 24). Both of these point mutations, H233L and H398P, are located on the X and Y catalytic domains of human PLCζ, respectively (see Fig. 4A), and they have been found to dramatically reduce in vitro PIP<sub>2</sub> hydrolysis activity (see Fig. 5B), fully consistent with their inability to produce the normal pattern of Ca<sup>2+</sup> release in mouse eggs, resulting in egg activation failure (see Fig. 4B). However, microinjection of wild-type human PLCζ protein into mouse eggs that were expressing these infertility-linked PLC mutants effectively rescued the failure of egg activation by inducing a normal pattern of Ca<sup>2+</sup> oscillations, leading to successful early embryo development up to the blastocyst stage (see Fig. 6).

These findings promote the potential application of PLC $\zeta$  protein into IVF clinics as an effective therapeutic option for egg activation failure due to male factor deficiencies related to PLC $\zeta$  dysfunction. It has previously been demonstrated that egg activation failure due to defective PLC $\zeta$  can be approached by using a Ca<sup>2+</sup> ionophore treatment during ICSI (26), even though this procedure does not specifically induce the characteristic Ca<sup>2+</sup> oscillations observed at fertilization (27). However, it currently remains to be determined whether such ionophore treatment represents the safest or most effective method for overcoming egg activation failure, as it is known that the precise pattern of Ca<sup>2+</sup> oscillations after fertilization in mouse eggs can exert potentially deleterious downstream, longer-term effects on both gene expression and embryo development (28).

The co-microinjection of PLC $\zeta$  cRNA during ICSI could, in principle, be used to rescue egg activation failure of PLC $\zeta$ -deficient sperm. This method would, however, present difficulties in practice because the rate of synthesis and total amount of PLC $\zeta$  protein expressed in the egg cannot be readily controlled using a bolus of microinjected cRNA. Previous studies have shown that successful embryo development requires PLC $\zeta$  to be present within the egg at a relatively precise concentration range to closely match the specific amount of PLC $\zeta$  that would be provided physiologically by the entry of a single mature sperm at fertilization (19). Thus, the availability of purified, active recombinant human PLC $\zeta$  protein appears to represent both a highly practical and the most physiologic therapeutic agent for overcoming failed ICSI cases resulting from aberrant sperm PLC $\zeta$ . Recombinant human PLC $\zeta$  protein could potentially also be used in regenerative medicine approaches via generation of parthenogenetic embryos and blastocysts that may facilitate stem cell derivation and differentiation.

### REFERENCES

- Kline D, Kline JT. Repetitive calcium transients and the role of calcium in exocytosis and cell cycle activation in the mouse egg. Dev Biol 1992;149: 80–9.
- Swann K, Yu Y. The dynamics of calcium oscillations that activate mammalian eggs. Int J Dev Biol 2008;52:585–94.
- Nomikos M, Swann K, Lai FA. Starting a new life: sperm PLC-zeta mobilizes the Ca<sup>2+</sup> signal that induces egg activation and embryo development: an essential phospholipase C with implications for male infertility. Bioessays 2011;34:126–34.
- Saunders CM, et al. PLC zeta: a sperm-specific trigger of Ca<sup>2+</sup> oscillations in eggs and embryo development. Development 2002;129:3533–44.
- Cox LJ, Larman MG, Saunders CM, Hashimoto K, Swann K, Lai FA. Sperm phospholipase Cζ from humans and cynomolgus monkeys triggers Ca<sup>2+</sup> oscillations, activation and development of mouse oocytes. Reproduction 2002;124:611–23.
- Kouchi Z, Shikano T, Nakamura Y, Shirakawa H, Fukami K, Miyazaki S. Recombinant phospholipase C zeta has high Ca<sup>2+</sup> sensitivity and induces Ca<sup>2+</sup> oscillations in mouse eggs. J Biol Chem 2004;279:10408–12.
- Knott JG, Kurokawa M, Fissore RA, Schultz RM, Williams CJ. Transgenic RNA interference reveals role for mouse sperm phospholipase C zeta in triggering Ca<sup>2+</sup> oscillations during fertilization. Biol Reprod 2005;72:992–6.
- Nomikos M, Blayney LM, Larman MG, Campbell K, Rossbach A, Saunders CM, et al. Role of phospholipase C-zeta domains in Ca<sup>2+</sup>-dependent phosphatidylinositol 4,5-bisphosphate hydrolysis and cytoplasmic Ca<sup>2+</sup> oscillations. J Biol Chem 2005;280:31011–8.
- Kouchi Z, Shikano T, Nakamura Y, Shirakawa H, Fukami K, Miyazaki S. The role of EF-hand domains and C2 domain in regulation of enzymatic activity of phospholipase Cζ. J Biol Chem 2005;280:21015–21.
- Nomikos M, Mulgrew-Nesbitt A, Pallavi P, Mihalyne G, Zaitseva I, Swann K, et al. Binding of phosphoinositide-specific phospholipase C-zeta (PLC-zeta) to phospholipid membranes: potential role of an unstructured cluster of basic residues. J Biol Chem 2007;282:16644–53.
- Nomikos M, Elgmati K, Theodoridou M, Calver BL, Nounesis G, Swann K, Lai FA. Phospholipase Cζ binding to PtdIns(4,5)P2 requires the XY-linker region. J Cell Sci 2011;124:2582–90.
- Phillips SV, Yu Y, Rossbach A, Nomikos M, Vassilakopoulou V, Livaniou E, et al. Divergent effect of mammalian PLCζ in generating Ca<sup>2+</sup> oscillations in somatic cells compared with eggs. Biochem J 2011;438:545–53.
- Nomikos M, Elgmati K, Theodoridou M, Georgilis A, Gonzalez-Garcia JR, Nounesis G, et al. Novel regulation of PLC<sup>2</sup> activity via its XY-linker. Biochem J 2011;438:427–32.
- Yu Y, Nomikos M, Theodoridou M, Nounesis G, Lai FA, Swann K. PLCζ causes Ca<sup>2+</sup> oscillations in mouse eggs by targeting intracellular and not plasma membrane Pl(4,5)P2. Mol Biol Cell 2012;23:371–80.
- Yoon SY, Jellerette T, Salicioni AM, Lee HC, Yoo MS, Coward K, et al. Human sperm devoid of PLC, zeta 1 fail to induce Ca<sup>2+</sup> release and are unable to initiate the first step of embryo development. J Clin Invest 2008;118: 3671–81.
- Heytens E, Parrington J, Coward K, Young C, Lambrecht S, Yoon SY, et al. Reduced amounts and abnormal forms of phospholipase C zeta (PLCζ) in spermatozoa from infertile men. Hum Reprod 2009;24:2417–28.
- Kashir J, Konstantinidis M, Jones C, Lemmon B, Lee HC, Hamer R, et al. A maternally inherited autosomal point mutation in human phospholipase C zeta (PLCζ) leads to male infertility. Hum Reprod 2012;27:222–31.

- Nomikos M, Elgmati K, Theodoridou M, Calver BL, Cumbes B, Nounesis G, et al. Male infertility-linked point mutation disrupts the Ca<sup>2+</sup> oscillation-inducing and PIP(2) hydrolysis activity of sperm PLC<sub>2</sub>. Biochem J 2011;434:211–7.
- Yu Y, Saunders CM, Lai FA, Swann K. Preimplantation development of mouse oocytes activated by different levels of human phospholipase C zeta. Hum Reprod 2008;23:365–73.
- Fitzsimmons TJ, Gukovsky I, McRoberts JA, Rodriguez E, Lai FA, Pandol SJ. Muliple isoforms of the ryanodine receptor are expressed in rat pancreatic acinar cells. Biochem J 2000;351:265–71.
- Swann K, Campbell K, Yu Y, Saunders CM, Lai FA. Use of luciferase chimaera to monitor PLCζ expression in mouse eggs. Methods Mol Biol 2009;518:17–29.
- Ito J, Parrington J, Fissore RA. PLCζ and its role as a trigger of development in vertebrates. Mol Reprod Dev 2011;78:846–53.
- Kashir J, Heindryckx B, Jones C, De Sutter P, Parrington J, Coward K. Oocyte activation, phospholipase C zeta and human infertility. Hum Reprod Update 2010;16:690–703.
- 24. Kashir J, Jones C, Lee HC, Rietdorf K, Nikiforaki D, Durrans C, et al. Loss of activity mutations in phospholipase C zeta (PLCζ) abolishes calcium

oscillatory ability of human recombinant protein in mouse oocytes. Hum Reprod 2011;26:3372–87.

- De Marco V, Stier G, Blandin S, de Marco A. The solubility and stability of recombinant proteins are increased by their fusion to NusA. Biochem Biophys Res Commun 2004;322:766–71.
- Taylor SL, Yoon SY, Morshedi MS, Lacey DR, Jellerette T, Fissore RA, Oehninger S. Complete globozoospermia associated with PLCzeta deficiency treated with calcium ionophore and ICSI results in pregnancy. Reprod Biomed Online 2010;20:559–64.
- Heindryckx B, De Gheselle S, Gerris J, Dhont M, De Sutter P. Efficiency of assisted oocyte activation as a solution for failed intracytoplasmic sperm injection. Reprod Biomed Online 2008;17:662–8.
- Ozil JP, Banrezes B, Toth S, Pan H, Schultz RM. Ca<sup>2+</sup> oscillatory pattern in fertilized mouse eggs affects gene expression and development to term. Dev Biol 2006;300:534–44.
- Yoon SY, Eum JH, Lee JE, Lee HC, Kim YS, Han JE, et al. Recombinant human phospholipase C zeta 1 induces intracellular calcium oscillations and oocyte activation in mouse and human oocytes. Hum Reprod 2012;27: 1768–80.